Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

N o thromboembolic events or related serious adverse events reported over 12-week observation period in FRONTIER1 study. 1

Novo Nordisk A/S: Mim8 phase 1 & 2 data demonstrates potential as once monthly treatment for people with haemophilia A

Medtronic

These stocks are worth buying whether or not a recession is coming.

2 Safe Stocks That Can Survive Any Downturn

Best Buy

Deere & Company

iShares MSCI EAFE ESG Optimized ETF

Microsoft

Procter & Gamble

Xylem

ESG investing has not been immune to declines in the current bear market The post ESG Investing: 7 Profitable Stock Picks for the Socially Responsible appeared first on InvestorPlace. More From InvestorPlace $200 Oil Sooner Than You Think – Buy This Now The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn't matter if you have $500 in savings or $5 million.

ESG Investing: 7 Profitable Stock Picks for the Socially Responsible

PARIS & BAGSVÆRD, Denmark--(BUSINESS WIRE)-- #NAFLD--Echosens and Novo Nordisk Announce Partnership to Increase Awareness and Advance Early Diagnosis of NASH

Echosens and Novo Nordisk Announce Partnership to Increase Awareness and Advance Early Diagnosis of NASH

Amylyx Pharmaceuticals

Alpha Tau Medical

Regeneron Pharmaceuticals

As the industry continues to make new discoveries, could biotech stocks be in focus?

4 Top Biotech Stocks To Watch Today

Johnson & Johnson

Predictive markets response to current equity price comparisons of this stock pair suggests value attraction for NVO and further decline in JNJ. Prior reward/risk coming price-range forecasts like the present have produced for JNJ average holding outcomes of only +0.1% price gains instead of the 9%+ hoped for.

Johnson & Johnson Or Novo Nordisk: Which Is The Best Big Pharma Near Cap-Gainer

Novo Nordisk – major shareholder announcement

Novo Nordisk A/S:

Novo Nordisk A/S (NVO) ADA 82nd Scientific Sessions Conference June 5, 2022 8:30 PM ET Company Participants Karsten Knudsen - Chief Financial Officer Martin Holst Lange - EVP and Head of Development Mads Frederik Rasmussen - Senior Vice President and Head of Clinical Drug Development Conference Call Participants Michael Novod - Nordea Markets Richard Vosser - JPMorgan Chase & Co Mark Purcell - Morgan Stanley Michael Nedelcovych - Cowen and Company Jesper Ilsoe - Carnegie Karsten Knudsen Welcome to the Novo Nordisk R&D event in conjunction with the ADA 2022 here in New Orleans in hot summer June. It's great to see all here, and we have a very nice R&D presentation coming up.

Novo Nordisk A/S (NVO) Presents at ADA 82nd Scientific Sessions (Transcript)

AP Moller - Maersk A/S

Atlas Copco AB

Carlsberg AS

Coloplast A/S

Orsted AS

Equinor

LM Ericsson Telefon

Mowi ASA

Norsk Hydro ASA

Nokia

Orkla ASA

Sampo Oyj

Sandvik AB

Stora Enso Oyj

Vestas Wind Systems A/S

Yara International ASA

A list of companies covering some of the world's strongest economies in Scandinavia. Diversification can take place not only across sectors but also across geographies, with opportunities here across pharma, logistics, oil, heavy industry, telecom, 5G, insurance, vehicles, conglomerates, and so forth.

The Scandinavian Shopping List In A Time Of Bargains

Bagsværd , Denmark , 3 June 2022 – Novo Nordisk today announced headline results from the main phases of ONWARDS 1 (52 weeks) and ONWARDS 6 (26 weeks) phase 3a trials with once-weekly insulin icodec.

Novo Nordisk achieves primary objectives of ONWARDS 1 and 6 trials with once-weekly insulin icodec demonstrating superior reduction in HbA1c vs insulin glargine U100 in ONWARDS 1

AutoZone

Hingham Institution for Savings

McCormick

Grupo Aeroportuario del Pacifico

Roper Technologies

Texas Instruments

Markets are shaky right now. But these seven best long-term stocks to buy and hold should work in just about any economic environment.

The 7 Best Long-Term Stocks to Buy and Hold Until 2032

GlaxoSmithKline

Eli Lilly

Merck

Drug/biotech companies are likely to see significant advances in innovation in 2022. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and Glaxo (GSK) are worth retaining in your portfolio.

4 Large Drug Stocks to Watch as the Industry Recovers

Advancing insulin technology promises a better patient experience.

How Novo Nordisk Will Protect Insulin Sales

Bagsværd, Denmark, 3 May 202 2 — Novo Nordisk A/S has today entered into an agreement to purchase 4,207,500 B shares of DKK 0.20 to a value of DKK 3,402 million from Novo Holdings A/S. This transaction is part of Novo Nordisk A/S' 2022 share repurchase programme of up to a total of DKK 24 billion to be executed during a 12-month period beginning 2 February 2022. The transaction price is DKK 808.51 per share and has been calculated as the three-day volume weighted average market price from 29 April 2022 to 3 May 2022 in the open window following the announcement of Novo Nordisk A/S' quarterly financial results.

Novo Nordisk A/S purchases B shares worth DKK 3,402 million from Novo Holdings A/S under the 2022 share repurchase programme

Incyte

Seagen

Which biotech stocks do you have on your May 2022 watchlist?

3 Top Biotech Stocks To Watch In May 2022

Novo Nordisk (NVO) reports better-than-expected results for Q1. Sales are aided by growth in Diabetes and Obesity Care on higher GLP-1 revenues.

Novo Nordisk's (NVO) Q1 Earnings and Sales Beat Estimates

Bagsværd , De n mark, 2 M ay 202 2 – Novo Nordisk today announced that the company has been notified by BlackRock, Inc. (Blackrock) as follows:

Bagsværd, Denmark, 2 May 202 2 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons on 29 April 2022

I'll review Novo Nordisk after a chat with one of my fellow contributors on the subject. The company is a popular holding due to its very liquid NYSE-listing NVO. I'll go through what makes the company good - and what makes it face competition here.

Novo Nordisk: Overvalued Pharma That Should Be Rotated Here

Biogen

Moderna

Vertex Pharmaceuticals

Let us take a look at some pharma/biotech stocks, REGN, BIIB, NVO, VRTX and MRNA that are poised to beat on first-quarter earnings.

5 Big Pharma, Biotech Stocks Set to Beat Q1 Earnings Estimates

Shares in Novo Nordisk jumped on Friday after the firm lifted its sales and operating profit guidance for the year on the back of forecast-beating first-quarter earnings, driven by strong sales of its newer diabetes and obesity treatments.

Novo Nordisk lifts 2022 outlook after strong quarter, shares jump

Financial report for the period 1 January 2022 to 31 March 2022

Novo Nordisk's sales increased by 24% in Danish kroner and by 18% at constant exchange rates to DKK 42.0 billion in the first three months of 2022

Novo Nordisk continues to hold its leading position in insulin and the anti-obesity drugs market space that are projected to grow steadily within the next several decades. It has all metrics to inflation-proof your portfolio as it has considerable pricing power and stable dividend payouts.

Novo Nordisk: Inflation Hedge With Upside Potential

Novo Nordisk reported strong growth in fiscal 2021 with revenue and earnings per share growing in the double digits. And due to anti-obesity medications and GLP-1 products, we can expect Novo Nordisk to continue its high growth rates.

Novo Nordisk: Firing On All Cylinders, Which Is Reflected By The Share Price

Sales of obesity therapies grew strongly first 3 quarters of 2021. Obesity and related diseases are increasing in both number of cases and geographic diversity.

Novo Nordisk: Growing Obesity Epidemic Will Generate Strong Demand

News for Novo Nordisk Stock (NVO)